Loading…
Lakewood-Amedex Biotherapeutics Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in LABT.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CDIOCardio Diagnostics Holdings, Inc. | $1.85 | — | 0.7x | — | -75.44% | $5.48M |
| CVKDCadrenal Therapeutics, Inc. | $1.54 | — | 1.2x | — | -275.16% | $5.49M |
| JUNSJupiter Neurosciences Inc | $4.18 | — | — | — | -1888.70% | $5.51M |
| PULMPulmatrix, Inc. | $1.51 |
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Company description provided by Yahoo Finance.
| — |
| 3.5x |
| — |
| -98.35% |
| $5.51M |
| PMCBPharmaCyte Biotech, Inc. | $0.52 | — | 0.2x | — | -44.72% | $5.53M |
| NCNANuCana plc | $1.33 | 0.0x | 0.2x | — | -70.26% | $5.54M |